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20% of ischemic strokes are linked to some 
form of arrhythmia [1], and in these patients, 
they tend to be more severe than in non‑ar‑
rhythmic patients [5]. About 40% of stroke 
survivors presents moderate to severe dis‑
ability; applying these rates to the prevalent 
population, it has been calculated that around 
384,000 are not autonomous in Italy due to 
stroke, and this figure is expected to rise up 
to 440,000 by 2020 [6].
Therapeutic goals in the management of AF 
patients include symptom control, but also 
the prevention of thromboembolic complica‑
INTRODUCTION
Atrial fibrillation (AF) is the most prevalent 
form of arrhythmia, involving about 1‑2% of 
the population in industrialized countries [1]. 
Its prevalence increases with age, reaching 
values above 5% in the over 65 years old, and 
of 9% in octogenarians [2].
In Italy, a prevalence of 600,000 AF patients 
was estimated for year 2010, and a further 
increase is expected due to the increasing 
age of the population and the improved sur‑
vival of cardiovascular patients [3]. Stroke 









OBJECTIVE: This study aims to perform a budget impact analysis of the use of three available novel oral anticoagulant 
agents (NOACs) for preventing thromboembolic events in Italian patients with non‑valvular atrial fibrillation (NVAF).
METHODS: Estimated Italian population of patients was run through a previously published lifetime decision tree/Markov 
model simulating their treatment with the available therapeutic options: dabigatran at two dose levels (110 mg/bid for the 
over 80 years old, 150 mg/bid for younger NVAF patients), rivaroxaban (20 mg/uid), and apixaban (5 mg/bid). Effective‑
ness and safety estimates derive from an adjusted indirect treatment comparison using warfarin as link. The main clinical 
events considered in the model are ischemic and hemorrhagic stroke, systemic thromboembolism, bleeds (both major and 
clinically relevant minor) and cardiovascular hospitalizations, besides treatment discontinuations. Epidemiological data 
and unit costs, actualized to 2013, are collected from Italian published sources. The budget impact analysis evaluates the 
financial impact of apixaban introduction by comparing expected 1,2, and 3 years costs in hypothetical scenarios: with and 
without apixaban. Italian NVAF patient population estimation is based on official apixaban reimbursement criteria, ap‑
plying the characteristics of the trial population to national epidemiologic data. Numbers of patients for each regimen are 
estimated by projecting share evolution. Sensitivity analysis is performed on an alternative non‑experimental population 
of NVAF patients.
RESULTS: Among available NOACs, apixaban was expected to be the least expensive in an estimated patient population of 
364,000 Italian patients, allowing for savings of € 1,180,549, € 3,841,429 and € 5,368,918 at 1,2, and 3 years, respectively. 
Results of the simulation run on an alternative non‑experimental population of NVAF patients yields comparable estimates.
CONCLUSIONS: The different safety and effectiveness profiles of the three available NOACs emerging from the adjusted 
indirect comparison indicate that apixaban could improve health care expenditure control while maintaining or increasing 
therapeutic appropriateness in the Italian NVAF population.
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tions, stroke in primis. This was traditionally 
pursued with the administration of vitamin 
K antagonists (VKA), or with antiplatelet 
agents, mainly aspirin, in subjects intoler‑
ant or contraindicated to VKAs [7]. In the 
last years, however, the class of novel oral 
anticoagulant agents (NOACs) has been in‑
troduced, which is associated with a more 
favourable risk/benefit ratio than VKAs. 
Until recently, dabigatran, a direct thrombin 
inhibitor, and rivaroxaban, a direct and se‑
lective coagulation factor Xa inhibitor, were 
the only NOACs licensed for thromboem‑
bolic prevention in non‑valvular AF (NVAF, 
about 70% of all AF cases). Apixaban, also 
a direct and selective coagulation factor Xa 
inhibitor [8], is facing the launch on the mar‑
ket for this indication, with the following re‑
imbursement restrictions: NVAF with both 
CHA2DS2‑VASc ≥ 1
1 and HAS‑BLED > 32, 
or time in therapeutic range (TTR) < 70% or 
objective difficulties in measuring INR [9].
Aim of the present analysis is the compara‑
tive, short‑term economic evaluation of the 
use of the three available NOACs in the 
prevention of thromboembolic events in the 
indicated Italian population of patients with 
NVAF. A budget impact analysis for the Ital‑
ian National Health Service, which covers 
both the pharmaceutical cost and the costs for 
management of clinical events is performed 
to evaluate the financial impact following the 
entry of apixaban among NOACs.
METHODS
The analysis is conducted with a simulation 
study, performed through the adaptation and 
run of an international previously published 
model [10,11] and executed with epidemio‑
logical, clinical practice and unit costs per‑
tinent to the Italian setting. The model is 
designed to reproduce the experience of a 
cohort of NVAF patients of user defined fea‑
tures, alternatively treated with the available 
therapeutic options: for the present study, 
dabigatran at two dose levels (110 mg/bid 
for the over 80 years old, 150 mg/bid for 
1 Calculates stroke risk for patients with atrial fibrillation, 
possibly better than the CHADS2 score. It is composed of 
7 domains: age (1 point for ages 65‑74, 2 points for > 74); 
gender (Female, 1 point); congestive heart failure history 
(yes, 1 point); hypertension history (yes, 1 point); stroke/TIA/
thromboembolism history (yes, 2 points), vascular disease 
history (yes, 1 point), and diabetes mellitus (yes, 1 point).
2 HAS‑BLED is an acronym for: Hypertension, Abnormal 
Liver/Renal Function, Stroke History, Bleeding Predisposi‑
tion, Labile INR, Elderly (Age > 65), Drugs/Alcohol Usage, 
with each of the domains scored 1 point if present, to be 
added up to obtain total score, which correlates with the 
risk of major bleeding. Estimates risk of major bleeding for 
patients on anticoagulation to assess risk‑benefit in atrial 
fibrillation care.
younger NVAF patients), rivaroxaban, and 
apixaban. During the simulation, events and 
consumed resources from the Italian National 
Health System perspective are recorded by 
the model; main clinical outcomes monitored 
are ischemic and hemorrhagic stroke, sys‑
temic thromboembolism, bleeds (both major 
and clinically relevant minor), cardiovascular 
hospitalizations, and death.
Model structure
The model is designed as a decision tree with 
Markov chains as branches; the experience 
of a NVAF patient is divided and represented 
in 17 possible and mutually exclusive health 
states (Figure 1). Transitions among health 
states are determined by probability matrices 
derived from the relevant literature as de‑
tailed elsewhere [11].
At the end of each 6 week cycle, patients 
can stay in the current health state, or ex‑
perience a clinical event and forward to the 
corresponding state; some events only imply 
a resource consumption, whilst others – i.e. 
stroke, myocardial infarction (MI), and sys‑
temic embolism – also modify the chance of 
incurring in further events. Stroke survivors 
distribute among subsequent health states 
basing on the assigned severity distribu‑
tion of the specific event. Following a major 
bleeding, patients may continue to receive 
the initial anticoagulant, or switch to a sec‑
ond line treatment, associated with specific 
clinical event risks.
Population
The simulation is run on two cohorts (Table 
I): the first (base‑case) reproducing clinical 
and demographic features of the ARISTO‑
TLE trail population [12], the second those 
of a non‑experimental population of NVAF 
patients studied by Olesen et al. [13]. In this 
cohort study, Olesen et al. assessed the indi‑
vidual risk factors composing the CHADS2 
and CHA2DS2‑VASc score calculating the 
capability of the schemes to predict thrombo‑
embolism in a nationwide cohort of Danish 
real‑world patients.
Clinical outcomes rates
In general, the model assigns baseline clinical 
risks basing on the demographic and clinical 
features of the patients; these risks evolve ac‑
cording to the time elapsed from the begin‑
ning of the simulation, to the risk‑modifying 
clinical events experienced by the patient, 
and to the preventive regimen administered.
The effectiveness and safety profile of apixa‑
ban reflects event rates recorded in the ARIS‑
TOTLE trial [12] integrated with patient‑lev‑
el data made available by Lip et al. [11], 
Figure 1. Simplified structure of the Markov model
Base‑case – ARISTOTLE 
population [12]
Alternative case – 
Real‑world population [13]
% males 65 53




> 2 30 24
Table I. Baseline characteristics of the simulated populations: base‑case patient 
populations, from ARISTOTLE trial [12], and alternative‑case population, from a 
nationwide cohort of real‑world patients, registered in the Danish patient registry [13]
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which showed that apixaban was associated 
with a reduction in the risk of stroke or sys‑
temic embolism, in bleeding, and in all‑cause 
mortality in AF patients, as compared to war‑
farin. The choice of the ARISTOTLE trial, 
a randomised head‑to‑head clinical trial, is 
related to the comparator, warfarin, which 
is common to the pivotal trials in AF of the 
other NOACs. The baseline risk profile can 
be adjusted for different distributions in the 
simulated population vs. the ARISTOTLE 
population of the CHADS2 and TTR, for 
stroke and bleeding, respectively.
Dabigatran was compared to warfarin in AF 
patients in the RELY trial, in which it demon‑
strated similar efficacy in stroke and throm‑
boembolic prevention and lower bleeding 
risk, at the 110 mg bid, and superior stroke 
and embolism prevention, with similar bleed‑
ing risk, at the 150 mg bid dose [14].
Rivaroxaban was compared to warfarin in the 
ROCKET‑AF trial, demonstrating non inferi‑
ority in the prevention of stroke and throm‑
boembolism in NVAF patients, and similar 
bleeding risk [15].
Data from the VKA‑suitable population 
of these trials (ARISTOTLE, RELY, and 
ROCKET‑AF) were included in indirect 
treatment comparisons, using warfarin as 
common comparator, to obtain relative risks 
younger NVAF patients), rivaroxaban, and 
apixaban. During the simulation, events and 
consumed resources from the Italian National 
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the model; main clinical outcomes monitored 
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and clinically relevant minor), cardiovascular 
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a resource consumption, whilst others – i.e. 
stroke, myocardial infarction (MI), and sys‑
temic embolism – also modify the chance of 
incurring in further events. Stroke survivors 
distribute among subsequent health states 
basing on the assigned severity distribu‑
tion of the specific event. Following a major 
bleeding, patients may continue to receive 
the initial anticoagulant, or switch to a sec‑
ond line treatment, associated with specific 
clinical event risks.
Population
The simulation is run on two cohorts (Table 
I): the first (base‑case) reproducing clinical 
and demographic features of the ARISTO‑
TLE trail population [12], the second those 
of a non‑experimental population of NVAF 
patients studied by Olesen et al. [13]. In this 
cohort study, Olesen et al. assessed the indi‑
vidual risk factors composing the CHADS2 
and CHA2DS2‑VASc score calculating the 
capability of the schemes to predict thrombo‑
embolism in a nationwide cohort of Danish 
real‑world patients.
Clinical outcomes rates
In general, the model assigns baseline clinical 
risks basing on the demographic and clinical 
features of the patients; these risks evolve ac‑
cording to the time elapsed from the begin‑
ning of the simulation, to the risk‑modifying 
clinical events experienced by the patient, 
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Table I. Baseline characteristics of the simulated populations: base‑case patient 
populations, from ARISTOTLE trial [12], and alternative‑case population, from a 
nationwide cohort of real‑world patients, registered in the Danish patient registry [13]
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or hazard ratios of each of the NOACs vs. 
apixaban, for each evaluated outcome [11] 
(Table I).
For apixaban, the risk of incurring an isch‑
emic stroke (IS) is directly extrapolated from 
the ARISTOTLE in the base‑case analysis, 
and adjusted for the CHADS2 distribution 
in Olesen et al. [13] for the alternative sce‑
nario; for the competing NOACs, the rate is 
calculated by applying the relevant HR to the 
apixaban hazard in both analyses. Increasing 
age is associated with higher IS risk; in the 
model, this is accounted for by applying a 
HR of 1.4 per decade [16]. Severity distribu‑
tion of IS is classified according to the modi‑
fied Rankin scale (mRS – mild 0‑2; moderate 
3‑4; severe 5 and fatal 6) specific to the AC 
treatment and was derived from published lit‑
erature (Table II).
As with IS, in the base‑case analysis the ab‑
solute intracranial hemorrhage (ICH) hazard 
rate for apixaban is directly obtained from 
ARISTOTLE; specific HRs are applied to 
these rates to determine the hazard rates for 
dabigatran and rivaroxaban. The model ac‑
counts for age‑related increase in ICH risk by 
applying a 1.97 HR per decade [17]. Hemor‑
rhagic strokes (HS) are determined as a treat‑
ment‑specific percentage of ICHs; similarly, 
their severity distribution, again expressed in 
terms of mRS, is treatment‑specific.
IS and HS survivors are at risk of recurrence: 
this is modelled according to a real‑life reg‑
istry indicating a cumulative incidence of 4.1 
and 3.0 per 100 patient‑years, respectively 
[18]; the severity distribution of recurrent 
strokes for all alternatives is conditional on 
the severity of the first stroke, as observed in 
ARISTOTLE and AVERROES [19].
As with IS and ICH, the model accounts for 
increasing MI risk with higher ages by apply‑
ing an HR of 1.30 per decade [20]. MI case 
fatality rates applied in the simulation are spe‑
cific for gender (10.8% in men and 15.6% for 
women), differently than for SE (9.4%) [21].
During the simulation, patients may dis‑
continue treatment, either completely, or by 
switching to another AC regimen, as a con‑
sequence of clinical events incurred, or for 
other reasons as described on Dorian et al. 
[10] and Lip et al. [11]
Besides the already described case fatality 








Aspirin (2nd line) 
[10,11]
IS*
Rate/100 pts‑yr 0.98 3.456
HR (95% CI) vs. apixaban 1.20 (0.88‑1.64) 0.82 (0.59‑1.14) 0.98 (0.72‑1.33)
Pts distribution (%)
 • Mild mRS (0‑2) 53 35 35 49 365
 • Moderate mRS (3‑4) 21 28 22 18 385
 • Severe mRS (5) 8 10 8 6 155
 • Fatal mRS (6) 18 27 35 27 115
ICH*
Rate/100 pts‑yr 0.33 0.326
HR (95% CI) vs. apixaban 0.73 (0.43‑1.26) 1.02 (0.62‑1.68) 1.73 (1.08‑2.77)
Other ICH (%) 23 36 59 43 455
Case Fatality Rates (%) 133 132 132 132 135
Proportion of HS (%) 77 64 41 57 555
 • Mild mRS (0‑2) 23 35 35 49 75
 • Moderate mRS (3‑4) 32 28 22 18 205
 • Severe mRS (5) 10 10 8 6 275
 • Fatal mRS (6) 35 27 35 27 465
Other MB*
Rate/100 pts‑yr 1.79 0.896
HR (95% CI) vs. apixaban 1.21 (0.97‑1.50) 1.37 (1.10‑1.70) 1.44 (1.15‑1.79)
Case Fatality Rates 23 22 22 22 25
Proportion of GI Bleeds 38 41 49 45 395
CRNM*
Rate/100 pts‑yr 2.08 2.946
HR (95% CI) vs. apixaban 1.16 (0.99‑1.35) 1.30 (1.11‑1.53) 1.49 (1.26‑1.76)
MI*
Rate/100 pts‑yr 0.53 1.116
HR (95% CI) vs. apixaban 1.474 (0.96‑2.27) 1.46 (0.95‑2.24) 0.94 (0.64‑1.38)
SE
Rate/100 pts‑yr 0.09 0.404
HR (95% CI) vs. apixaban 12 12 12
Other CV Hosp
Rate/100 pts‑yr 10.461 13.576
HR (95% CI) vs. apixaban 12 12 12
Other Treat Disc
Rate/100 pts‑yr 13.18 ‑
HR (95% CI) vs. apixaban 1.45 (1.31‑1.61) 1.51 (1.36‑1.67) 1.18 (1.08‑1.29)
Background mortality°
Rate/100 pts‑yr 3.08 ‑
HR (95% CI) vs. apixaban 12 12 12
Table II. Summary of main clinical inputs used in the analysis
CRNM: Clinically Relevant non Major Bleeds; GI: Gastro‑Intestinal Bleeds; HS: Hemorrhagic Stroke; ICH: IntraCranial Hemorrhages; IS: Ischemic Stroke; 
MI: Myocardial Infarction; Other CV Hosp: Other Cardio‑Vascular Hospitalization; Other MB: other Major Bleeds; Other TreatDisc: Other Treatment 
Discontinuation; pts: patients; SE: Systemic Embolism; yr: year
1 Assume same rate as the apixaban’s rate observed among the VKA unsuitable population
2 Assume same risk as apixaban
3 Pooled sample percentages
4 Assume same rate as ASA first line observed in the VKA unsuitable population
5 Assume same distribution as ASA first line
6 Subgroup of patients who had VKA‑unsuitability “demonstrated” (i.e., previously failed warfarin)
* Stroke, bleeds and MI risks are adjusted over time to take into account the increased risks with aging: HR for adjunctive decade of 1.4 [16], 1.97 [17], 
and 1.3 [20], respectively, are applied
° For the duration of the trial follow‑up
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or hazard ratios of each of the NOACs vs. 
apixaban, for each evaluated outcome [11] 
(Table I).
For apixaban, the risk of incurring an isch‑
emic stroke (IS) is directly extrapolated from 
the ARISTOTLE in the base‑case analysis, 
and adjusted for the CHADS2 distribution 
in Olesen et al. [13] for the alternative sce‑
nario; for the competing NOACs, the rate is 
calculated by applying the relevant HR to the 
apixaban hazard in both analyses. Increasing 
age is associated with higher IS risk; in the 
model, this is accounted for by applying a 
HR of 1.4 per decade [16]. Severity distribu‑
tion of IS is classified according to the modi‑
fied Rankin scale (mRS – mild 0‑2; moderate 
3‑4; severe 5 and fatal 6) specific to the AC 
treatment and was derived from published lit‑
erature (Table II).
As with IS, in the base‑case analysis the ab‑
solute intracranial hemorrhage (ICH) hazard 
rate for apixaban is directly obtained from 
ARISTOTLE; specific HRs are applied to 
these rates to determine the hazard rates for 
dabigatran and rivaroxaban. The model ac‑
counts for age‑related increase in ICH risk by 
applying a 1.97 HR per decade [17]. Hemor‑
rhagic strokes (HS) are determined as a treat‑
ment‑specific percentage of ICHs; similarly, 
their severity distribution, again expressed in 
terms of mRS, is treatment‑specific.
IS and HS survivors are at risk of recurrence: 
this is modelled according to a real‑life reg‑
istry indicating a cumulative incidence of 4.1 
and 3.0 per 100 patient‑years, respectively 
[18]; the severity distribution of recurrent 
strokes for all alternatives is conditional on 
the severity of the first stroke, as observed in 
ARISTOTLE and AVERROES [19].
As with IS and ICH, the model accounts for 
increasing MI risk with higher ages by apply‑
ing an HR of 1.30 per decade [20]. MI case 
fatality rates applied in the simulation are spe‑
cific for gender (10.8% in men and 15.6% for 
women), differently than for SE (9.4%) [21].
During the simulation, patients may dis‑
continue treatment, either completely, or by 
switching to another AC regimen, as a con‑
sequence of clinical events incurred, or for 
other reasons as described on Dorian et al. 
[10] and Lip et al. [11]
Besides the already described case fatality 
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CRNM: Clinically Relevant non Major Bleeds; GI: Gastro‑Intestinal Bleeds; HS: Hemorrhagic Stroke; ICH: IntraCranial Hemorrhages; IS: Ischemic Stroke; 
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1 Assume same rate as the apixaban’s rate observed among the VKA unsuitable population
2 Assume same risk as apixaban
3 Pooled sample percentages
4 Assume same rate as ASA first line observed in the VKA unsuitable population
5 Assume same distribution as ASA first line
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and 1.3 [20], respectively, are applied
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lation is subjected to a background mortal‑
ity derived from ARISTOTLE for the dura‑
tion of the trial follow‑up; given the lack of 
sound comparative mortality rates, the same 
background mortality has been applied to all 
NOACs.
Beyond the trial duration, mortality is pro‑
jected based on Gompertz distributions fitted 
on Italian age‑ and gender‑specific popula‑
tion rates [22], corrected for the HRs associ‑
ated to AF, MI, stroke, and SE, as shown in 
Table III.
COSTS
Costs are evaluated from the perspective of 
the National Health System (SSN); accord‑
ingly, only direct health care costs are con‑
sidered:
 ‑ Drug acquisition costs, at negotiated net 
prices [28] (Table IV);
 ‑ Routine visits [29] for all treated patients;
 ‑ Acute event management (strokes, 
bleeds, myocardial infarction, and other 
CV hospitalizations);
 ‑ Long‑term post‑event management for 
stroke, MI, and SE;
 ‑ Other health care costs associated with 
AC management (Table V).
Stroke management costs have been elabo‑
rated basing on data reported in an observa‑
tional study conducted on 411 Italian stroke 
survivors, followed up for 12 months [30]: 
for each severity category within ischemic 
and hemorrhagic strokes, the mean long‑term 
maintenance cost has been approximated 
to the monthly cost recorded in the second 
semester; the costs for the acute phase cor‑
respond to the sum of the corresponding 
DRG tariff [31] and the difference between 





Stroke [24‑26] MI [27]
SE*
Mild Moderate Severe Female Male
HR 1.34 3.18 5.84 15.75 4.16 2.56 1.34
Table III. Death hazard ratios according to the health condition of the simulated patient
* Assumption
Drug Daily dose (mg/die) Daily cost (€)
Aspirin 100 0.04
Apixaban 10 1.90
Dabigatran (110 mg) 220 1.90
Dabigatran (150 mg) 300 1.90
Rivaroxaban 20 1.80
Table IV. Drug acquisition costs, at negotiated net prices [28]
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to RELY data), equalled to the corresponding 
tariff of € 8.16 [31].
All historical cost data have been actualized 
to 2013 values using official indices [22] 
(Table V).
Budget impact analysis
The budget impact analysis evaluates the fi‑
nancial impact of apixaban introduction by 
comparing expected 1,2, and 3 years cost in 
two hypothetical scenarios: with and without 
apixaban.
Total, undiscounted costs per patient esti‑
mated by the simulation for the considered 
regimens are applied to the corresponding 
Unit cost (€) Unit Duration Source
Routine visit 15.37 per visit N/A Lucioni et al. [29]
Ischemic Stroke
Mild
 • Acute 4,663.06 per episode 2 weeks Fattore et al. [30]
 • Maintenance 81.76 per month Simulation length Fattore et al. [30]
Moderate
 • Acute 6,137.96 per episode 2 weeks Fattore et al. [30]
 • Maintenance 139.04 per month Simulation length Fattore et al. [30]
Severe
 • Acute 10,311.34 per episode 2 weeks Fattore et al. [30]
 • Maintenance 327.95 per month Simulation length Fattore et al. [30]
Fatal 3,891.00 per episode N/A DRG 14 [31]
Hemorrhagic stroke
Mild
 • Acute 6,321.14 per episode 2 weeks Fattore et al. [30]
 • Maintenance 118.11 per month Simulation length Fattore et al. [30]
Moderate
 • Acute 10,073.43 per episode 2 weeks Fattore et al. [30]
 • Maintenance 200.86 per month Simulation length Fattore et al. [30]
Severe
 • Acute 20,932.42 per episode 2 weeks Fattore et al. [30]
 • Maintenance 473.77 per month Simulation length Fattore et al. [30]
Fatal 3,891 per episode N/A DRG 14 [31]
Other ICH 25,812 per episode N/A DRG 528 [31]
Other major bleeding 3,317 per episode N/A DRG 174 [31]
CRNMB 2,091 per episode N/A DRG 175 [31]
IM
 • Acute 6,275.21 per episode N/A Mantovani et al. [32]
 • Maintenance 157.97 per month Simulation length Mantovani et al. [32]
SE
 • Acute 4,663.06 per episode 2 weeks Assumption
 • Maintenance 81.76 per month Simulation length Assumption
Other CV hospitalization 4,742 per episode N/A DRG 479 [31]
Table V. Cost inputs
For acute and long‑term MI management, 
cost data are elaborated basing on three‑year 
follow‑up data reported for Italian MI sur‑
vivors [32]. The costs attributed to the other 
clinical events considered are equalled to the 
corresponding DRG‑based tariff paid to hos‑
pitals by the Italian NHS [31].
Other AC related costs considered are relat‑
ed to dyspepsia management (€ 71.46/year 
[33], rates of dyspepsia from ARISTOTLE 
for apixaban and warfarin, from adjusted 
indirect comparison for dabigatran, and as‑
sumed equal to apixaban for rivaroxaban) 
and to renal function monitoring for dabiga‑
tran treated patients at risk (19.4%, according 
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market shares estimated for the two scenarios 
at 1,2, and 3 years. Numbers of patients for 
each regimen are estimated by projecting 
share evolution based on IMS market re‑
search [34].
RESULTS
In Table VI, main results of the simulation for 
all alternatives at 1,2, and 3 years are shown: 
among available NOACs, it can be seen that 
apixaban results the least expensive in all 
considered years.
The target population is estimated in about 
364,000 patients (Table VII), calculated by 
applying a 1.7% AF prevalence rate [35], of 
which 70% are NVAF subjects, to the Ital‑
ian resident population, and considering that 
about 50% satisfy the criteria for reimburse‑
ment issued by AIFA, i.e. CHA2DS2‑VASc ≥ 1 
and HAS‑BLED > 3 (9,38%) [36,37], or TTR 
< 70% (40%) [38] or objective difficulties in 
measuring INR.
It has to be noted that the eligible patient pop‑
ulation identified by AIFA through these cri‑
teria appears inconsistent with the assigned 
pharmaceutical expense cap for the class, 
indicated by AIFA itself in 60 M €/year: it 
can be easily calculated (basing on an ap‑
proximate cost of 650 €/year per patient) that 
this budget is sufficient to cover a maximum 
of about one fourth of the patients who are 
expected to benefit the most from the avail‑
ability of the innovative NOACs.
The expected penetration of NOACs on the 
market in the next three years has been es‑
timated based on the market evolution from 
the approval of NVAF as indication for the 
NOACs (Table VIII); in the scenario in 
which apixaban is present, an increasing per‑
centage of the NOAC – treated population is 
prescribed apixaban, with shares subtracted 
proportionally to the comparators, as shown 
in Table VIII. Cumulative cost estimates, as 
estimated by the model and shown in detail 
in Table VI are applied to the resulting patient 
numbers for each regimen and added up to 
obtain the expected budget dedicated to the 
target population: the budget impact is calcu‑
lated as the difference among the total costs 
expected without and with the introduction of 
apixaban.
Resulting patient numbers per regimen are 
displayed in Table VIII, alongside the ex‑
pected cumulative impact: under the detailed 
assumptions, the introduction of apixaban 
will temper the cost associated with expand‑
ing market shares of NOACs, allowing for 
savings of over 5 million € by the third year.
Main results of the simulation run on 
non‑experimental population of NVAF pa‑
Strategy
Total cost (€)
Year 1 Year 2 Year 3
Apixaban 1,425 2,961 4,436
Dabigatran (110 mg) 1,449 2,992 4,461
Dabigatran (150 mg) 1,459 3,007 4,476
Rivaroxaban 1,459 3,020 4,511
Table VI. Base‑case: main simulation results
% N Source
Residents in Italy 61,175,388 ISTAT [22]
AF Prevalence 1.70 1,039,982 Bollettino Ufficiale 
Regione Veneto [35]
NVAF 70 727,987 ESC, 2010 [1]
AIFA criteria* 50 363,994 Friberg, 2012 [36]; 
ATA‑AF, 2013 [37]; 
Nichol, 2008 [38]
Table VII. Target population per BI
* About 50% of patients satisfy the criteria for reimbursement issued by AIFA: NVAF with 
both CHA2DS2‑VASc ≥ 1 and HAS‑BLED > 3, or time in therapeutic range (TTR) < 70% or 
objective difficulties in measuring INR
Year 1 Year 2 Year 3
Common scenario
Target pts (n.) 363,994 363,994 363,994
NOACs
 • n. 71,204 133,481 150,559
 • % 20 37 41
Warfarin
 • n. 292,790 230,513 213,435
 • % 80 63 59
Scenario w/o apixaban
Dabigatran 110 mg (n.) 20,107 36,551 40,654
Dabigatran 150 mg (n.) 25,383 46,144 51,323
Rivaroxaban (n.) 25,714 50,786 58,582
Apixaban (n.) 0 0 0
Scenario w/ apixaban
Dabigatran 110 mg (n.) 9,414 14,093 11,407
Dabigatran 150 mg (n.) 11,884 17,792 14,401
Rivaroxaban (n.) 12,039 19,582 16,437
Apixaban (n.) 37,867 82,014 108,314
BI (€) ‑1,180,549 ‑3,841,429 ‑5,368,918
Table VIII. Base‑case – Budget impact
tients [13] for all alternatives at 1, 2, and 3 
years are presented in Table IX. Resulting 
expected financial impact obtained by ap‑
plying these results to the identified target 
population are displayed in Table X, and 
substantially confirm the estimates of the 
base‑case analysis.
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impact of systematically choosing just one of 
the NOAC for this indication, and to detail 
how the different cost components are affect‑
ed by such a choice. The excess pharmaceu‑
tical cost, due to improved persistence with 
the prescribed AC regimen with apixaban, is 
completely offset by reduced costs for event 
management, leading to the overall per pa‑
tient saving already shown in Table VI.
CONCLUSIONS
The expected economic differences among 
NOACs stem from the different safety and 
effectiveness profile of the NOACs emerging 
from the adjusted indirect comparison.
Dabigatran, at the 110 mg BID dose, appears 
associated with a lower ICH risk than apixa‑
ban, but this should be traded off with an ap‑
parently reduced protection against ischemic 
strokes; the latter may be mitigated with the 
higher dabigatran dose (150 mg BID) or with 
the use of rivaroxaban, but at the expense of 
much higher bleeding risks; however from 
a health economics point of view, neither 
trade‑off is expected to be efficient.
In conclusion, analyses based upon dem‑
onstrated relative effectiveness and safety 
profiles indicate that the different balance 
between ischemic protection and increased 
bleeding risk is more favourable with apixa‑
ban than with the other NOACs from a health 
economics perspective: the pharmacoeco‑
nomic analyses performed and the findings 
presented in this paper clearly support the 
value of apixaban in Italian NVAF patients.
Its use in these patients, when compared with 
other NOACs, is expected to have the poten‑
tial for relevant savings (between € 8.8 mil‑
lion and € 27.3 million), which are linked to 
its intrinsic effectiveness and to the lowest 
discontinuation rate among its class members 
(it is known that to maintain preventive effec‑




Dabigatran (110 mg) Dabigatran (150 mg) Rivaroxaban
Anticoagulants 49,632,106 55,842,014 52,540,069
Ischemic Stroke ‑24,362,893 ‑922,257 ‑365,284
Hemorrhagic Stroke 9,372,101 12,084,733 ‑3,367,459
Systemic Embolism ‑973,544 ‑1,137,583 ‑459,840
Other bleedings ‑16,016,517 ‑50,508,295 ‑73,677,525
MI + CV hospitalizations ‑24,207,752 ‑27,540,021 ‑2,158,969
Other* ‑2,276,000 ‑2,265,143 206,011
Total cost ‑8,832,500 ‑14,446,551 ‑27,282,998
Table XI. Potential BI at three years, detailed by component (n. = 363,994)
* Other costs include routine care visit and health care costs associated with AC management
A comparison of total costs accruing after 
three years for the treatment of the whole 
identified patient population with one of the 
available NOACs is presented in Table XI, in 
order to highlight the total potential budget 
Regimen
Total cost (€)
Year 1 Year 2 Year 3
Apixaban 1,419 2,942 4,366
Dabigatran (110 mg) 1,441 2,971 4,385
Dabigatran (150 mg) 1,454 2,992 4,413
Rivaroxaban 1,453 3,004 4,445
Table IX. Real world population [13] – main simulation results
Year 1 Year 2 Year 3
Common scenario
Target pts (n.) 363,994 363,994 363,994
NOACs
 • n. 71,204 133,481 150,559
 • % 20 37 41
Warfarin
 • n. 292,790 230,513 213,435
 • % 80 63 59
Scenario w/o apixaban
Dabigatran 110 mg (n.) 20,107 36,551 40,654
Dabigatran 150 mg (n.) 25,383 46,144 51,323
Rivaroxaban (n.) 25,714 50,786 58,582
Apixaban (n.) 0 0 0
Scenario w/ apixaban
Dabigatran 110 mg (n.) 9,414 14,093 11,407
Dabigatran 150 mg (n.) 11,884 17,792 14,401
Rivaroxaban (n.) 12,039 19,582 16,437
Apixaban (n.) 37,867 82,014 108,314
BI (€) ‑1.190.296 ‑3.971.151 ‑5.568.785
Table X. Real world population [13] – budget impact analysis
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